Emerging Predictive Biomarkers for Targeted Therapies in NSCLC

Download these slides from a live CCO Webinar for an overview of emerging biomarkers and targeted therapies showing promise in the treatment of advanced NSCLC.
Stephen V. Liu, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.90 MB
Released: April 14, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
Lilly
Regeneron Pharmaceuticals, Inc & Sanofi Genzyme

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

Download these expert-selected slides on slides on treating patients with NTRK-positive tumors with TRK inhibitors, from Clinical Care Options (CCO).

Alexander Drilon, MD Released: June 11, 2021

Download these expert-selected slides on slides on overcoming acquired resistance with TRK inhibitors, from Clinical Care Options (CCO).

Theodore Laetsch, MD Released: June 11, 2021

Download these expert-selected slides on testing for TRK fusions in your patients with cancer, from Clinical Care Options (CCO).

George D. Demetri, MD Released: June 11, 2021

Updated 2-year results from CheckMate 9LA evaluating nivolumab plus ipilimumab with chemotherapy vs chemotherapy from ASCO 2021, as reported by Clinical Care Options (CCO)

Released: June 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue